文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

转移性视网膜母细胞瘤新型临床前平台的建立与全面表征以促进治疗开发

Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

研究从7例转移性视网膜母细胞瘤患者的眼眶肿瘤、骨髓、脑脊液和淋巴结浸润标本中建立原代细胞系和异种移植模型,成功建立5个原代细胞系(2个来自软脑膜、2个来自眼眶、1个来自淋巴结播散),经玻璃体腔或脑室内接种建立细胞来源异种移植模型。原代细胞系和异种移植模型准确保留了来源肿瘤的组织学和基因组特征,并忠实再现了匹配患者中观察到的播散模式和药物敏感性。

要点

  • 成功建立5个转移性视网膜母细胞瘤原代细胞系:2个来自软脑膜、2个来自眼眶、1个来自淋巴结播散。
  • 原代细胞系和异种移植模型保留了来源肿瘤的组织学和基因组特征,再现了匹配患者的播散模式和药物敏感性。
  • 该平台旨在理解这一高度侵袭性肿瘤的生物学并识别当前缺乏有效治疗选择患者的候选药物。

核心结论

  • 研究建立了一个创新的、全面表征的转移性视网膜母细胞瘤临床前平台,用于理解该高度侵袭性肿瘤的生物学,并具有识别治疗当前缺乏有效治疗选择患者的候选药物的潜力。

研究设计与样本

  • 从7例转移性视网膜母细胞瘤患者的眼眶肿瘤、骨髓、脑脊液和淋巴结肿瘤浸润标本中获取标本,标本来自诊断、疾病进展或复发时。
  • 将肿瘤标本移植到免疫缺陷动物中,并建立原代细胞系。
  • 进行基因组学、免疫组织化学/免疫细胞化学和药理学分析。

主要发现

  • 成功建立5个原代细胞系:2个来自软脑膜、2个来自眼眶、1个来自淋巴结肿瘤播散。
  • 经玻璃体腔或脑室内接种这些细胞后,建立了细胞来源异种移植模型。
  • 原代细胞系和异种移植模型准确保留了来源肿瘤的组织学和基因组特征,并忠实再现了匹配患者中观察到的播散模式和药物敏感性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although there have been improvements in the management of metastatic retinoblastoma, most patients do not survive, and all patients suffer from multiple short- and long-term treatment toxicities. Reliable and informative models to assist clinicians are needed. Thus we developed and comprehensively characterized a novel preclinical platform of primary cell cultures and xenograft models of metastatic retinoblastoma to provide insights into the molecular biology underlying metastases and to perform drug screening for the identification of hit candidates with the highest potential for clinical translation. METHODS: Orbital tumor, bone marrow, cerebrospinal fluid, and lymph node tumor infiltration specimens were obtained from seven patients with metastatic retinoblastoma at diagnosis, disease progression, or relapse. Tumor specimens were engrafted in immunodeficient animals, and primary cell lines were established. Genomic, immunohistochemical/immunocytochemical, and pharmacological analysis were performed. RESULTS: We successfully established five primary cell lines: two derived from leptomeningeal, two from orbital, and one from lymph node tumor dissemination. After the intravitreal or intraventricular inoculation of these cells, we established cell-derived xenograft models. Both primary cell lines and xenografts accurately retained the histological and genomic features of the tumors from which they were derived and faithfully recapitulated the dissemination patterns and pharmacological sensitivity observed in the matched patients. CONCLUSIONS: Ours is an innovative and thoroughly characterized preclinical platform of metastatic retinoblastoma developed for the understanding of tumor biology of this highly aggressive tumor and has the potential to identify drug candidates to treat patients who currently lack effective treatment options.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zugbi S, Aschero R, Ganiewich D, et al. Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments. Invest Ophthalmol Vis Sci. 2023. PMID: 38117242. doi:10.1167/iovs.64.15.27

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。